Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — 9M 2019/20 Earnings Presentation
11 slides from Coloplast A/s Class B's earnings presentation, Aug 18, 2020
Slide 1: Making it easier to be yourself
Making it easier to be yourself Clothes are a part of my identity, so I worried about what I could wear after my operation. Today, I still dress the way I want. Stina Coloplast Earnings Conference Call 9M 2019/20 18 August 2020 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and I
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast strengthens Executive Management
Coloplast strengthens Executive Management • Coloplast Executive Leadership Team is expanded from four to six people in order to deliver on upcoming 2025 strategy centred around Innovation and Growth, which will be presented at the Capital Markets Day on September 29th Kristian Villumsen New role EV
Slide 4: Q3 negatively impacted by decline in elective procedures in Interventional Urology and reversal of stock building in EU
Q3 negatively impacted by decline in elective procedures in Interventional Urology and reversal of stock building in EU Q3 Highlights Revenue growth +5% • Negative organic growth of -2% and -4% reported decline in DKK Reported revenue (DKKm) +5% • Chronic Care delivered a stable underlying growth in
Slide 5: Q3 significantly impacted across all business areas and regions by COVID-19
Q3 significantly impacted across all business areas and regions by COVID-19 Revenue by business area Revenue by geography Business Reported revenue Q3 Organic growth Organic growth Geographic Reported revenue Q3 Organic growth Organic growth area DKKm Q3 YTD area DKKm Q3 YTD Ostomy Care 1,870 4% 8%
Slide 6: 9M 2019/20 reported revenue grew 5% driven by organic growth of 5%
9M 2019/20 reported revenue grew 5% driven by organic growth of 5% Comments Revenue development • 9M 2019/20 reported revenue increased by DKK 633m (DKKm) or 5% compared to 9M 2018/19 635 13,954 • The majority of growth was driven by organic growth -2 contributing DKK 635m or 5% to reported revenue
Slide 7: EBIT grew 7% in 9M 2019/20 reflecting strong cost control during COVID-19 outbreak
EBIT grew 7% in 9M 2019/20 reflecting strong cost control during COVID-19 outbreak as well as sustained investments Comments EBIT margin development (%) • Gross margin of 68% in DKK compared to 67% last year • Positive impact driven by GOP4 and the closure of the Thisted factory 0.1 -0.1 in June 201
Slide 8: FCF driven by positive underlying development in earnings
FCF driven by positive underlying development in earnings FCF development Comments • Free cash flow in 9M 2019/20 was DKK 2,436m, up 10% compared to DKK 2,215m in 9M 2018/19 98 99 98 • Adjusted for the positive impact of DKK 144m related to the 93 96 92 reclassification of lease payments following t
Slide 9: Financial guidance for FY 2019/20 – guidance range narrowed
Financial guidance for FY 2019/20 – guidance range narrowed Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • The situation in Interventional Urology gradually normalises in Q4 • Majority of 150m stock building from Q2 reversed in Q3 – expected to ~4% fully reverse in Q4 3-4% Sales growth f
Slide 10: Capital Markets Day 2020
Capital Markets Day 2020 14.00 pm - 17.00 pm CEST 13.00 pm - 16.00 pm BST 08.00 am - 11.00 am EDT Join us virtually or at our venue in Humlebaek, north of Copenhagen. This event is intended to give institutional investors and equity analysts an introduction to the new long-term strategy. More inform
Slide 11: Our mission, values and vision
Our mission Making life easier for people with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | us Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /